Higher Medicine Inc. today announced a strategic investment and clinical development agreement with 5 Horizons Capital, LLC (“5HC”), a U.S.-based investment firm focused on early-stage life sciences innovation.
Under the agreement, 5HC has committed to an equity investment valued at $181,492 in support of Higher Medicine’s upcoming Phase 1b/2a clinical trial in a rare pediatric disorder.
5 Horizons Capital partners with emerging biotechnology companies through flexible, founder-aligned financing structures, with a focus on neurology, immunology, and rare diseases. The investment will be made as an in-kind equity contribution, and 5HC will adopt the same valuation terms as the company’s lead investor. The agreement is non-binding and subject to the completion of additional due diligence and final documentation.
Clinical execution will be supported by Novotech, a leading Australia-based clinical research organization (CRO) with global operations. Known for its strength in early-phase clinical execution, Novotech offers a compelling environment for streamlined trial launch—potentially including Australian regulatory and operational advantages.
The commitment is contingent upon execution of a trial startup agreement or letter of intent with Novotech, which will lead operational delivery of the study.
“We’re excited to contribute to the advancement of a novel therapeutic program with strong mechanistic rationale and clinical momentum,” said Aaron Ray, Co-Founder and Managing Partner of 5Horizons Capital. “Higher Medicine’s focused approach and scientific rigor align with our mission to support transformative early-stage biotech.”
The transaction is expected to close upon initiation of trial startup activities, representing a strategic step in accelerating the company’s path to first-in-human data.
About 5 Horizons Capital, LLC
5 Horizons Capital is a U.S.-based investment firm focused on advancing early-stage biotechnology companies through the critical transition into clinical development. The firm specializes in supporting first-in-human trials by providing not only capital, but also strategic insight and validation to help emerging therapies navigate early clinical milestones. With a focus on high-impact areas such as neurology, rare diseases, and immunology, 5 Horizons Capital partners closely with founding teams to accelerate innovation, de-risk development, and drive long-term value creation. For more information, visit www.5horiz.com
About Novotech
Novotech is a global full-service clinical research organization (CRO) specializing in early- to mid-phase clinical development. The company combines deep regional regulatory expertise with scalable clinical operations to deliver high-quality, accelerated trial execution. Services include feasibility assessments, regulatory submissions, data management, safety monitoring, and ICH-compliant reporting. For more information, visit www.novotech-cro.com